Moclobemide in depression: a randomized, multicentre trial against isocarboxazide and clomipramine emphasizing atypical depression
| Autor: | E. Høyer, A. Bille, O. J. Rafaelsen, John Sahl Andersen, Jens Knud Larsen, B. Nilakantan, A. Langagergaard, Annette Gjerris, A. L. Laursen, P. Holm, H. V. Jensen, A. Mejlhede, K. Olafsson, E. M. Christensen, B. Severin |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
Male Clomipramine Isocarboxazid medicine.drug_class Moclobemide law.invention Orthostatic vital signs Double-Blind Method Randomized controlled trial law Anticholinergic medicine Humans Atypical depression Aged Psychiatric Status Rating Scales Depressive Disorder Monoamine oxidase inhibitor business.industry Middle Aged medicine.disease Antidepressive Agents Psychiatry and Mental health Anesthesia Benzamides Female business medicine.drug |
| Zdroj: | Acta Psychiatrica Scandinavica. 84:564-570 |
| ISSN: | 1600-0447 0001-690X |
| DOI: | 10.1111/j.1600-0447.1991.tb03196.x |
| Popis: | Moclobemide was compared with isocarboxazide and clomipramine in patients with depression. A total of 167 outpatients were allocated to daily treatment with 300 mg moclobemide, 30 mg isocarboxazide or 150 mg clomipramine for 6 weeks. Moclobemide was slightly inferior to clomipramine, whereas isocarboxazide had an intermediate position. There was no interaction between treatment and atypical or nonatypical depression. Anticholinergic symptoms and orthostatic hypotension were most pronounced in the clomipramine group. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text